secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0001178913-24-003556
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio Q3 net loss $3.0M ($0.08/shr); cash $6.9M; awaits FDA SABRE ruling Jan 2025
--------------------------------------------------------------------------------

- Net loss of $3.0M ($0.08 basic/diluted EPS) for Q3 2024 vs $2.4M ($0.08) in Q3 2023; operating expenses $3.0M vs $2.4M.
- Cash and equivalents $6.9M; expects runway into Q3 2025.
- EB613 (oral PTH) phase 3 prep ongoing; FDA decision on SABRE regulatory endpoint expected January 2025.
- Oral GLP-1/glucagon (with OPKO) showed favorable PK/PD; plans to present at clinical conference.
- Oral GLP-2 tablet for short bowel syndrome; final PK/PD data expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891324003556/0001178913-24-003556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891324003556/zk2432254.htm
  HTML page:      https://secwatch.observer/filing/0001178913-24-003556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer